personalis.com (PSNL): Operating Profitability

Corporate emblem and logo of Personalis, Inc. (PSNL)

Personalis, Inc. (PSNL) relies on cloud IT solutions to store genomic data arrays. Reviewing the operating profit margin dynamics on GURU.Markets, we see that the -156.70 metric determines this level. Growing demand for early recurrence diagnostics is expanding the market, yet stringent regulatory filters and medical insurance complexities create significant barriers to scaling the business.

PSNL: Personalis Operating Margin 07/04/2022 - 11/19/2026

PSNL (personalis.com): analytical breakdowns and indicator data

- price and consensus price forecast:
- stock exchange capitalization data:
Initial company analysis:Personalis Corp
Finished products of Personalis, Inc.

Operating margin determines cost management efficiency relative to revenue. By analyzing changes in core business margins, an investor assesses the company's ability to generate profit before interest and taxes. The metric is calculated as the ratio of operating income to total sales. For Personalis, Inc. (PSNL), this metric is critical due to large-scale R&D investments. High capex and reliance on pharma partners make the margin the primary indicator of the biotech's financial stability.

Competitor analysis for Personalis, Inc.

Operating Profitability BeiGene Ltd|Halozyme Therapeutics - Operating Profit Margin|Operating Sales Margin RVMD (Revolution Medicines Corp)|Operating Profit Ratio AAPG|Operating Profitability CG Oncology Therapeutics CGON|Operating Profit Rate URGN|BCAX: Operating Sales Margin|Profitability of Operations Erasca Oncology ERAS|delcath.com (DCTH) - Operating Profitability|Y-mAbs Therapeutics - Operating Profit Rate|AURA (Aura Biosciences Inc) - Operating Margin|Operating Return on Sales candeltx.com CADL|Operating Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Operating Profit Rate|Operating Profitability Actuate Therapeutics, Inc. ACTU|citiusonc.com - Operating Profitability|TuHURA Biosciences Inc. - Operating Margin|TARA - Operating Margin|FATE (Fate Therapeutics) - Operating Sales Margin|Operating Sales Margin Aadi Bioscience, Inc.|Operating Sales Margin TCRX|Operating Profitability CSBR|Operating Margin XBIT|Profitability of Operations CEL-SCI Corp.|Operating Profitability ostherapies.com OSTX|RADX: Return on Sales by Operating Profit|ARTV: Operating Sales Margin|ANL (Adlai Nortye) - Return on Sales by Operating Profit|Veru (VERU) - Operating Profitability|Operating Sales Margin Tempest Therapeutics Inc|Operating Profitability Xilio Therapeutics|Return on Sales by Operating Profit RENB (Renovaro Inc.)|Operating Profitability Mural Oncology PLC (MURA)|Operating Margin Kairos Pharma (KAPA)|Operating Profitability onkuretherapeutics.com OKUR|GDTC: Return on Sales by Operating Profit|CRIS: Operating Sales Margin|apollomicsinc.com (APLM) - Operating Sales Margin|THAR: Operating Margin|Operating Sales Margin Advanced Biomed Inc.|Operating Sales Margin GNPX|Return on Sales by Operating Profit CLDI (Calidi Biotherapeutics)|Operating Margin SBFM|Xenetic Biosciences, Inc. - Return on Sales by Operating Profit|Operating Profitability Salarius Pharmaceuticals SLRX|Operating Margin purple-biotech.com PPBT|AONC - Operating Profitability|BGNE: Operating Profitability|CKPT: Operating Margin|Elevation Oncology - Operating Profit Rate|ICAD (iCAD) - Operating Margin|IKNA: Operating Profit Rate|Operating Profitability Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operating Profit Rate|Operating Profitability MorphoSys Corporation MOR|NAYA: Return on Sales by Operating Profit|Ascentage Pharma Group International - Operating Margin